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1. Introduction 
 
1.1. Epidemiology, Risk Factors and Pathology of Prostate Cancer 
 
1.1.1. Epidemiology 
 
Prostate cancer (PCa), or carcinoma of the prostatic gland, is a malignant 
transformation within the prostatic gland. It is considered as the second most 
common cancer and the sixth leading cause of cancer death in men worldwide 
(Center, 2012). Around 15% of men today are expected to be diagnosed with PCa 
in future (Siegel, 2014). From 1975 to 1980, the annual incidence rate had increased 
by 2%. This was explained by the incidental detection of PCa after the transurethral 
resection of the prostate for benign prostatic hyperplasia (Potosky et al., 1990). After 
the introduction of prostate-specific antigen (PSA) and screening programs for PCa, 
the incidence rates had dramatically increased between 1989 and 1992 (Siegel et 
al., 2014). With the detection of undiagnosed cases, the incidence rates then 
decreased between 1992 and 1995, followed by a return to baseline detection rates 
(Stephenson et al., 1996). PCa has displayed a wide variation of incidences 
worldwide; it is the most common type of non-skin malignancy which affects men in 
USA and Europe. Incidences range up to 249 cases per 100,000; especially in 
African Americans who have a 59% higher incidence rate than whites (Siegel et al., 
2014). On the other hand, the lowest incidence rate (1.9 cases per 100,000) was 
detected in China (Jemal et al., 2006; Parkin et al., 2005). PCa can be incidentally 
found during a histopathological examination of radical cystoprostatectomy 
specimens after a radical cystectomy for muscle invasive bladder cancer, with a 
suggested pathological correlation between both malignancies (Fahmy et al., 2017). 
In general, PCa is a slow-growing cancer. Among the common solid 
malignancies, PCa is associated with the lowest mortality rate (Liu et al., 2013). 
Before 1991, it was the single leading cause of death among men diagnosed with 
PCa (35%) After 1991, a decline of the mortality rate was observed, which was 
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explained by the introduction of PSA in screening, as well as increased utility of 
effective curative treatments (Epistein, 2012). Mortality rates due to PCa widely vary 
between countries and ethnic groups; the highest rates were reported in the 
Caribbean (28 per 100,000 yearly); however, in China and North Africa, the mortality 
rate is less than 5 per 100,000 yearly (Parkin et al., 2005). Over the last 2 decades, 
the mortality rate has decreased in 27 out of 53 analysed countries; however, in 
contrast, 10 countries have displayed an increase. The downward trend is mainly 
present in high-income countries where PSA-screening programs are well- 
established. On the other hand, an increased mortality rate was noticed in central 
and eastern Europe, Asia and Africa (Rebbeck, 2013). The average age of death 
due to PCa has remained stable at 77 years over the last three decades (Epstein et 
al., 2012). 
Currently, no clear data can explain the observed variation in the incidence and 
mortality rate due to PCa, which is likely due to a multi-factorial process. People of 
the same race who live in different countries have varied rates of diagnosed PCa. 
For example, Chinese and Japanese men who immigrated to the US are at higher 
risk of PCa than those living in China and Japan. This could be due to different 
lifestyles, or environmental and dietary factors (Shimizu et al., 1991). 
1.1.2. Risk factors 
 
Various aspects were investigated as risk factors for PCa; for instance, age, 
family history, genes, race, inflammation and infection, hormones, sexual activity, 
vasectomy, diet, obesity, smoking and alcohol consumption. Among these factors, 
increasing age, heredity and ethnic origin are the main three well-known risk factors 
for PCa (Mottet et al., 2015). 
Most PCa cases occur for those above the age of 50 at the time of diagnosis. 
Only 2% are diagnosed before the age of 50 (Jani et al., 2008). Prior to the 
introduction of PSA, the median age of diagnosis was 70 years. Over the past two 
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decades, it decreased to 67 years, and 63% of cases were diagnosed after the age 
of 65 (Ries et al., 2008). Currently, the percentages of diagnosed PCa for men below 
55, 55-64, 65-74, 75-84 and above 85 are 10%, 30%, 35%, 20% and 4%, 
respectively (Brawley et al., 2012). 
 
A strong familial component for PCa was demonstrated by many 
epidemiological and genetic studies. Germline factor is considered to be responsible 
for about 15% of PCa cases (Carter et al., 1992). Suggestions for higher risk among 
first-degree relatives began early at the mid of the previous century (Woolf et al., 
1960). If the father is affected, the relative risk is 2.17 and it increases to 3.34 if the 
brother is affected. The risk further increases at least 5- folds if more than one first- 
degree relative is affected (Jansson et al., 2012; Hemminki et al., 2012). Early 
genetic studies had identified several genes expected to be responsible for PCa 
prevalence (HPC1, RNASEL, HPC2/ELAC and MSR1), yet the roles of these genes 
are not fully understood (Eeles et al., 2014). RNASEL alleles, in a population-based 
study, was identified as a predictive gene for PCa mortality (Lin et al., 2011). 
Recently, a new technique to identify PCa-associated alleles, named genome wide 
associated studies (GWAS), had identified alleles on chromosomes 2, 3, 4, 5, 6, 7, 
8, 10, 11, 12, 13, 17, 19, 22 and 
X. Yet, the predictive value for each allele is about 1.5 times the baseline risk, which 
makes the clinical benefit for identifying people at risk of PCa very limited 
(Choudhury et al., 2012; Eeles et al., 2014). Studies on African-Americans and 
Japanese populations have identified extra specific alleles for these groups, 
however the evidence is incomplete (Takata et al., 2010; Haiman et al., 2011). 
In general, chronic inflammation caused by infection can cause cancer by the 
induction of cellular hyperproliferation. This process is approved in cancer of the 
colon, stomach, bladder and liver (Coussens & Werb, 2002; DeMarzo et al., 2007). 
A similar mechanism for PCa was suggested after the frequent identification of 
proliferative inflammatory atrophy (PIA) in prostate specimens. Usually, PIA is found 
adjacent to the high-grade prostatic intraepithelial neoplasm 
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(HGPIN) or early PCa lesions (Shah et al., 2001; Nakayama et al., 2003). 
Furthermore, genetic alteration of genes responsible for inflammatory response and 
DNA repair were suggested to contribute to inflammation induced PCa (Klein & 
Silverman, 2008). Sexual activity has been suggested as a cause of prostatic 
inflammation with subsequent PCa. This was based on the increased incidence of 
PCa observed among uncircumcised men, and those with history of sexually 
transmitted diseases; especially syphilis (Sutcilffe et al., 2010). Despite the 
extensive effort conducted to isolate or identify specific infectious agents which may 
have a direct link with PCa initiation, currently, no infectious agent has been proven 
to cause PCa. 
Numerous studies have investigated dietary factors and obesity as causes of 
PCa after an increased incidence in the first generation of immigrants (from Asia to 
USA) was observed (Muir et al., 1991; Shimizu et al., 1991). However, until now, no 
study could show an association between food and PCa or establish any role 
between healthy food and the minimisation of risk of this disease. 
Obesity is a known risk factor for cancers, such as breast and colon cancers. 
White fat in human bodies is considered an endocrine organ that secretes cytokines 
and substances with cytokine-like activities (Madigan et al., 1998). Prospective 
studies suggest that obesity increases the risk of high-grade PCa but is also 
associated with lower risks of the low-grade disease (Gong et al., 2006). Obesity is 
further linked with higher rates of biochemical failure after radiotherapy or radical 
prostatectomy (Masko et al., 2013). 
Smoking is also a risk factor for PCa because it increases the circulating 
androgens and cadmium exposure. Moreover, it causes cellular oxidative stress 
(Huncharek et al., 2010). Based on recent studies, smokers are at higher risk of 
metastasis in comparison to non-smokers (Moreira et al., 2014). Alcohol 
consumption also demonstrated a controversial relation to PCa; epidemiological 
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studies have suggested higher risk of high-grade PCa in heavy drinkers (Zuccolo 
et al., 2013), while others suggested a protective role (McGregor et al., 2013). 
1.1.3. Pathology 
 
Adenocarcinoma is the most common type of PCa (Mottet et al., 2015). 
Mucinous adenocarcinoma is a rare subtype of adenocarcinoma with more liability 
to bone metastasis; however, the prognosis is similar to non-mucinous variants 
(Osunkoya et al., 2008). Sarcomas very rarely affect the prostate (less than 0.2%) 
and are more likely to be rhabdomyosarcoma or liomysarcoma in childhood or adult 
aged patients, respectively (Sexton et al., 2001; Cheville et al., 1995). 
Clinically undetectable tumours are staged as T1a/b if the cancer is 
incidentally found in the prostatic tissue after transurethral resection of the prostate 
(TURP), or after open prostatectomy for benign hyperplasia. This depends on the 
percentage of malignant tissue (T1a less than 5%; T1b more than 5%). Tumours 
detected after prostatic biopsy due to high PSA levels are staged as T1c (Epstein et 
al., 2007). After radical prostatectomy, preoperative T1 stages will be upstaged to 
T2 if the tumour is confined to the prostate, T3a if the tumour has extracapsular 
extension, or T3b if the tumour invades seminal vesicle. The degree of extracapsular 
extension correlates with the risk of disease progression after radical prostatectomy 
(Epstein et al., 2001). The tumour can extend to the seminal vesicle, more commonly 
through invasion of the periseminal vesicle’s soft tissue rather than direct extension 
through the ejaculatory duct (Villers et al., 1989). Seminal vesicle infiltration is a 
strong predictor for disease progression after surgery and is associated with a 65% 
progression rate within five years (Pierorazio et al., 2011). Most tumours are located 
in the posterior part of the prostate, in the peripheral zone. Only 15% of tumours arise 
from the anterior part, the transitional zone (Al-Ahmadie et al., 2008). In about 90% 
of cases, the tumour is multi-focal with a prominent nodule most often larger in size 
with higher grade and stage; however, other tumours are usually small and low 
grade (Yoon et al., 2008). The 
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most common sites for metastasis of PCa are the lymph nodes, bones and lungs. 
The less common sites include the bladder, liver and adrenal gland (Hess et al., 
2006). In general, the volume of the tumour correlates with the stage. Tumours less 
than 0.5 cm3 are unlikely to extend beyond the capsule. In most cases, tumours less 
than 4 cm3 are not associated with lymph node metastasis. However, the location of 
the tumour also affects the volume; for instance, transitional zone tumours extend 
beyond the capsule at larger volumes compared to peripheral zone tumours 
(McNeal et al., 1990). 
Grading of PCa is based on the Gleason system, which is founded on the 
glandular pattern of the tumour under low magnification. The pattern is graded from 
1 to 5, which is the most undifferentiated architecture (Gleason & Mellinger, 1974). 
Currently, the Gleason score is the sum of the most common and highest grade 
patterns instead of the sum of the first and second common patterns. If the tumour 
only has a single pattern, the score will be double the present pattern grade (Epstein 
et al., 2005). It is not advisable to grade a cancer as Gleason score of 2 to 4 based 
on needle biopsy because almost all tumours would be graded higher after radical 
prostatectomy (Steinberg et al., 1997). 
Different techniques can be used for prostate specimen sampling after radical 
prostatectomy. Whole-mount technique is the preferred method for teaching and 
publication purposes, however, the information provided is identical to those 
obtained from other techniques in which the prostate is not completely embedded 
(Sehdev et al., 2001). 
1.2. Surgical Anatomy of the Prostate 
 
The prostatic gland is an ovoid-shaped organ that lies below the bladder in the 
retropubic space and is traversed by the prostatic urethra; the junction between the 
bladder neck and membranous urethra. It has anterior, posterior and lateral surfaces 
with the prostatic base facing the bladder neck upwards, while the apex faces 
downwards. The deep position of the apex and the close relation to the 
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striated sphincter and the neurovascular bundle makes the apical dissection the 
most challenging step in RP. 
 
 
1.2.1. Prostatic capsule and endo-pelvic fascia 
 
The prostatic gland is surrounded by three separate layers of fascia: 
Denonvilliers fascia, the levator fascia and the prostatic fascia, which is also called 
the prostatic capsule. Denonvilliers fascia is a connective tissue layer that separates 
the prostate from the anterior wall of the rectum. Cranially, it becomes more dense 
and prominent; however, causally, it becomes thinner and terminates in the striated 
urethral sphincter. Prostatic fascia is in direct contact with prostatic parenchyma, 
anteriorly and laterally. The average thickness of the prostatic capsule is 0.5 mm 
and may be pierced in some areas by the glandular tissue. Laterally, the prostate is 
covered by the visceral endopelvic fascia, and the lateral divisions of the dorsal 
venous plexus are located between the prostatic capsule and the endopelvic fascia 
just below the arcus tendineus fascia pelvis (the juncture of the parietal and visceral 
endopelvic fascia). During classical radical prostatectomy, endopelvic fascia should 
be incised laterally to this junction to avoid injury of the venous plexus. 
1.2.2. Neurovascular bundle (NVB) 
 
Understanding the arterial and venous blood supply of the prostate is crucial to 
minimise intraoperative blood loss, as well as for proper visualisation of the 
prostatic apex and membranous urethra. Prostatic veins drain into the Santorini 
plexus. The superficial dorsal vein travels between the puboprostatic ligaments and 
can be easily visualised in the retropubic space over the prostate and bladder neck. 
The common trunk and the lateral venous plexus run between the prostatic fascia 
and endopelvic fascia. The lateral plexus has free communications with the 
pudendal, obturator and vesical plexuses and communicates with the internal 
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pudendal vein through small branches that penetrate the pelvic sidewall muscles 
near the puboprostatic ligament. 
Arterial supply for the prostate originates from the inferior vesical artery, a 
branch of the internal iliac artery through two large groups of arteries; the urethral 
and capsular groups (Flucks, 1937). The urethral branches enter the prostate at 
the posterolateral aspect of the bladder neck and supply the periurethral part of the 
gland. The capsular branches run posterolateral to the prostate, in the lateral pelvic 
fascia, and send dorsal and ventral branches to the prostate and pelvic floor. These 
capsular branches are the anatomical landmark for identifying the neurovascular 
bundle intraoperatively (Walsh et al., 1983). 
The cavernous nerve fibres run with the arterial supply of the prostate to form 
the NVB, which is mainly located at the posterolateral aspect of the prostate and 
pierce the prostate at 5 and 7-o’clock positions near the base. Approaching the 
apex, the NVB follows a spray-like distribution and pierces the prostate at 1 and 
11-o’clock positions. The nerve fibres are difficult to identify intraoperatively; the 
accompanying vessels are usually used as a landmark to preserve NVB during 
nerve sparing radical prostatectomy. 
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Figure 1(A): A cross section through the apex of the prostate demonstrating that the 
neurovascular bundles are posterolateral to the circumferential striated sphincter of the 
urethra. Figure 1(B): A cross section through the midportion of the prostate demonstrating 
that the neurovascular bundles are located between the layers of the levator fascia and 
prostatic fascia (Campbell-Walsh et al., 2012). 
 
 
Although the previous pattern is common for NVB distribution, anatomical 
variations in the distribution pattern of NVB around the prostate is not uncommon. 
In the literature, there is some evidence that nerve tissue is distributed not only in 
the posterolateral aspect, but also anteriorly (Eichelberg et al., 2007; Sievert et 
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al., 2008; Ganzer et al., 2008; Lee et al., 2008), and is even shown to have 
functionality (Hisasue et al., 2010). 
 
Figure 2: Distribution of periprostatic nerves. Transverse whole-mounted sections of the 
prostate from the apex (A) and the middle (B). Magnifications: (C) dorsal periprostatic and 
capsular nerves at the apex; (D) ventrolateral periprostatic nerves in the middle (Ganzer et 
al., 2008). 
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1.2.3. External urethral sphincter 
 
The striated urethral sphincter is located at the level of the membranous 
urethra. With the surrounding fascia, the sphincter forms a vertically-oriented tubular 
sheath around the membranous urethra and extends to the perineal muscle before 
the development of the prostate. After the prostate develops from the urethra, it 
invades the sphincter and causes some atrophy to the muscle fibres (Oelrich, 1980). 
In adults, the sphincter fibres form a horse-shoe shape around the membranous 
urethra and the apex of the prostate. This orientation is critical during the dissection 
of the apex to preserve the sphincter (Walsh et al., 1990). Apart from the Levator 
ani muscle, it also surrounds the membranous urethra and prostatic apex and is 
inserted posteriorly in the perineal body (Myers, 1994). These muscle fibres are 
responsible for voluntary active continence and are innervated at the striated 
sphincter by the pudendal nerve. The striated sphincter is responsible for passive 
continence through its fatigue-resistant, slow twitch fibres. Preoperative instructions 
for the patient to contract the levator ani muscle can help strengthen the external 
sphincter as well (Centemero et al., 2010). 
1.3. Role of Radical Prostatectomy in Treatment of PCa 
 
Radical prostatectomy (RP) is the surgical treatment for PCa. It involves the 
removal of the whole prostatic gland between the urethra and bladder, including the 
seminal vesicles and sufficient surrounding tissue, to obtain a negative margin. 
Many years ago, radical prostatectomy was recognised as the gold standard 
treatment for localised PCa (Christopher et al., 2016). This operation was developed 
in 1945 by an Irish surgeon, Terence Millin (Millin et al., 1945), and was refined in 
1982 by Patrick C. Walsh when he developed the modern nerve-sparing, retropubic 
prostatectomy with minimal blood loss to preserve the potency of patients (Walsh et 
al., 1983). The most common approach is to make an incision in the skin between 
the umbilicus and top of the pubic bone. Since the initial 
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description by Walsh, technical advancements have been made, and the incisional 
length has decreased to between 8–10 cm. 
Patients who undergo RP for low risk PCa can obtain better metastasis-free 
and progression-free survivals in comparison to patients who undergo watchful 
waiting of their disease (Hamdy et al., 2016). In intermediate risk disease, RP can 
significantly improve the overall survival, but not disease-specific survival, for PCa 
patients (Wilt et al., 2012). In high-risk PCa, RP can still be offered as a treatment 
option, however, it should be as part of a multi-modal treatment plan (Fahmy et al., 
2017). For patients who develop local recurrence after radiotherapy, salvage RP is 
the preferred option for local control of the disease, yet the rate of complications is 
expected to be higher than primary RP due to the impact of previous RT on the 
tissues (Chade et al., 2012). 
Commonly, this operation is accompanied by bilateral pelvic lymph node 
dissection; however, the indication for lymphadenectomy depends on the risk 
stratification of the disease. In low risk patients, pelvic lymph node dissection is not 
required since the chance of lymph node involvement in this group is very low. In 
intermediate-risk men, the chance of lymph node involvement is between 3.7% to 
20% (Studer et al., 2008). Pelvic lymphadenectomy should be performed if the risk 
of lymph nodes being positive is more than 5% (Studer et al., 2008). In all high-risk 
patients, lymphadenectomy should be routinely performed due to the high risk of 
lymph node involvement (15%-40%) (Studer et al., 2008). This includes, at least, 
the removal of lymph nodes around the external iliac vessels, medial and lateral to 
the internal iliac artery, and within the obturator fossa. Perisacral and common iliac 
lymph nodes can also be removed to maximise the chance of complete clearance 
of up to 97% (Mattei et al., 2008). 
1.4. Robotic Assisted Radical Prostatectomy (RARP) 
 
The first laparoscopic prostatectomy was performed in 1991 by William 
Schuessler et al. in Texas to minimise the morbidity of open surgery and overcome 
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the difficult exposure of the retropubic space during open radical prostatectomy 
(Schuessler et al., 1997). In 2000, the first RARP was performed by Binder et al. in 
Frankfurt, Germany (Binder et al., 2001) and by Abbou et al. in Creteil, France 
(Abbou et al., 2000). It then gained popularity over time (Frota et al., 2008). In 2010, 
Bocciardi described the subtrigonal approach through the Douglas space, following 
a completely intrafascial plane without any dissection of the anterior compartment 
(Galfano et al., 2010). Currently, 80-85% of radical prostatectomies in USA are 
performed using robotic assistance; however, this proportion is lower in Europe 
(Naomi, 2014). 
RARP began in the urology department at University Hospital Tuebingen in 
2008 and was performed using transperitoneal radical prostatectomy (TPRP) 
approach. In June 2013, the Tuebingen group switched to subtrigonal radical 
prostatectomy (STRP). This study compares the outcome of both techniques 
regarding the oncological and functional aspects. 
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2. Methodology 
 
2.1. Study Design and Data Collection 
 
For this study, the approval of the internal review board (IRB) and ethical 
committee in Tuebingen University was obtained (project number 709/2013BO2). 
All patients who underwent STRP in Tuebingen university hospital were identified 
from the beginning of this technique (June 2013) until January 2015. The research 
in the database displayed 92 patients treated with STRP between the specified 
timeframe. The first 30 patients who were operated in the second half of 2013 were 
excluded from the study since they were considered to be from the starting phase 
during the learning curve of this technique. Thus, 62 patients who underwent 
operation between January 2014 and January 2015 were included as the 
experimental group and were assigned to group B. To compare the outcomes of 
STRP versus TPRP, all patients who underwent operation using the TPRP 
technique in the last 18 months before starting STRP (from January 2012 to June 
2013) were identified as the control group and assigned to group A. 127 patients 
were retrieved for this group. A total of 189 patients were identified for both groups; 
127 patients from group A that underwent TPRP, and 62 patients from group B that 
underwent STRP. One patient was excluded from group A since TPRP was 
intraoperatively converted to open surgery due to severe adhesions from multiple 
previous surgeries. Finally, 188 patients were included in this study. No patients 
were excluded from the study based on preoperative or postoperative assessments. 
Data was prospectively collected from the database of Tuebingen University 
Hospital. The retrieved data included patients’ name, contact data, age, BMI, 
preoperative PSA, preoperative and postoperative haemoglobin level, digital rectal 
examination findings, preoperative Gleason score, TRUS estimated prostatic 
volume and potency status before surgery. The applied risk stratification was based 
on D’ Amico (D’ Amico et al., 1998). Operative data included console time 
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(the time taken by the surgeon on the robotic console), nerve sparing (either 
unilateral or bilateral) and intraoperative complications classified according to the 
Clavien-Dindo classification (Clavien et al., 2009). Blood loss was calculated by the 
difference between pre and post-operative haemoglobin levels. The final pathology 
data included the final Gleason score, prostatic specimen volume, margin status and 
lymph node status. Oncological outcomes were retrieved from the database which 
included the PSA relapse (biochemical recurrence was defined as the PSA level of 
≥0.2 ng/ml), development of metastasis and further treatment after surgery. 
Regarding functional outcomes, the data were collected from patients through 
phone calls or correspondences, as will be explained later. 
2.2. Surgical Technique 
 
All patients included in this study were treated with RARP for PCa after proper 
and full preoperative assessment. A well-informed written consent was obtained 
from every patient, including possible postoperative complications and the 
discussion of radiotherapy as an alternative treatment. TPRP was performed in the 
first group, while STRP was the employed technique in the second group. 
2.2.1. Conventional robotic assisted radical prostatectomy 
 
Under general anaesthesia, the patient is positioned in a supine position with 
semi-flexion and abduction of both hip joints, as well as flexion of the knee joints. A 
20F Foley catheter is inserted to deflate the bladder. Five laparoscopic ports are 
fixed in the abdominal wall in the following distribution: a 12 mm port at the umbilical 
ring for the robotic camera. After insufflation of Co2 of up to 15 mmHg pressure 
inside the abdominal cavity, two 8 mm ports on the line between the umbilicus and 
the anterior superior iliac spine are placed one hand breadth apart from the camera 
port on the line. One 5 and one 12 mm ports are on the right side for the assistant; 
the 5 mm port is between the camera and the 8 mm port and is used for suction. 
The 12 mm port is 8 cm below and lateral to the right 8 mm port and is used for the 
introduction of different surgical instruments employed by the 
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assistant surgeon. The patient’s position is changed from supine to deep 
Trendelenburg position after the fixation of all ports. 
 
 
Figure 3: A diagram demonstrating the distribution of laparoscopic ports in the 
abdominal wall (Fahmy et al., 2015). 
 
 
The pelvic cavity is inspected, and the release of adherent bowel is performed 
if necessary. An incision in the lower part of the anterior wall of the Douglas pouch 
using monopolar scissors is created. Next, the vas deference is identified as well as 
the seminal vesicle, which lies immediately lateral to it. Dissection of the seminal 
vesicle is performed by using minimal electrocautery and metal hemoclips to avoid 
thermal injury of the nearby NVB. Then, the retropubic 
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space is reached through the dissection of the perivesical fat. After controlling the 
dorsal venous plexus by using bipolar electrocautery, the bladder neck is dissected 
from the prostatic base using monopolar scissors. During this time, intermittent 
caudal retraction of the urethral catheter balloon is performed by the assistant 
surgeon to identify the proper plane for bladder neck dissection. Dissection is then 
continued towards the prostatic apex, and the urethra is sharply cut just above the 
concavity of the prostatic apex. 
 
 
Figure 4: Sharp dissection of the urethra from the prostatic apex (Fahmy et al., 
2015). 
Anterior traction over the vas and seminal vesicle is performed by the assistant 
surgeon to identify the space between the prostate and the rectum. After that, 
Denonvilliers fascia is incised just behind the junction of the ejaculatory duct 
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and prostate to reach the perirectal fat plane. Metallic clips are used to control the 
neurovascular bundles when nerve sparing was planned. After the complete 
dissection of the prostate, the remnant Denonvilliers fascia and posterior part of the 
bladder neck are approximated to the striated sphincter behind the urethral stump 
using the V-LocTM suture. With the same suture, a continuous tension-free vesico- 
urethral anastomosis is performed over a 20 Fr. Silicone catheter. The catheter 
balloon is then inflated with 8cc water. The anastomosis is tested for leakage by 
inflation of the bladder through the urethral catheter with 100 cc normal saline. 
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Figure 5: A diagram demonstrating the dissection planes in TPRP marked in the 
interrupted blue line (Patel & Chapple., 2008). 
2.2.2. Subtrigonal robotic assisted radical prostatectomy 
 
The patient’s position and distribution of the laparoscopic ports are the same as 
in conventional RARP. Seminal vesicles are directly approached through a lower 
transverse incision at the anterior wall of the Douglas pouch. After the dissection of 
the seminal vesicles and cutting of the vase deferentia bilaterally, the assistant 
surgeon applies upwards traction on the seminal vesicles to facilitate the incision of 
the posterior layer of the Denonvelliers fascia. The plan between the prostate and the 
rectum is opened just below the ejaculatory duct ( Fahmy et al., 2015). 
Subsequently, nerve sparing is achieved by retracting one seminal vesicle 
upwards and medially , and creating various holes in the periprostatic fascia and 
applying metal clips over the tissue bundles. The same technique is made on the 
contralateral side. After that, the base of the prostate is dissected form the bladder 
neck, starting form 6 o’clock , and continue bilaterally until 12 o’clock ( Fahmy et al., 
2015). 
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Figure 6: Bladder neck dissection from 6 o’clock until 12 o’clock (Fahmy et al., 2015). 
 
 
 
Lastly, external sphincter muscle fibers are peeled downward from the prostatic 
apex before cutting the urethra to minimize the sphincter injury . Then, the urethra is 
sharply cut just a few millimetres above the concavity of the prostatic apex. With this 
technique, the operation is completely performed through the Douglas pouch without 
entering the retropubic space or disruption of the peri-vesical tissue. The 
urethrovesical anastomosis is performed as described in the conventional technique. 
(Fahmy et al., 2015). 
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Figure 7: The view of the prostatic bed after complete extraction of the prostate with 
intact perivesical tissue (Fahmy et al., 2015). 
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Figure 8: A diagram demonstrating the dissection planes in STRP marked in the 
interrupted orange line (Patel & Chapple., 2008). 
 
 
2.3. Follow-up 
 
For patients treated with TPRP, the median follow-up time was 34 months (24- 
39). For STRP patients, the median follow-up time was 9 months (3-15). The data 
for perioperative outcomes including operative time, blood loss, intra- operative 
complications, hospital stay, anastomotic complications, duration of catheterisation 
and postoperative complications were collected from the database 
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records of Tuebingen University Hospital. Surgical complications were classified 
according to the Clavien-Dindo classification (Clavien et al., 1992). Marginal status 
was obtained from the histopathological examination of prostatic specimens using 
the whole-mount technique. BCR was defined as the PSA value of 0.2 ng/mL or 
greater with a second confirmatory laboratory value (Cookson et al., 2007). 
Functional outcomes were evaluated using ICIQ and IIEF scores for continence and 
potency, respectively. Incontinence was defined as using at least one pad per day. 
Immediate post-operative continence was defined as the no usage of pads within 
one week of catheter removal. Postoperative potency was defined as the ability of 
the patient to get enough erection for penetration with or without medications. Data 
for ICIQ and IIEF scores of patients were collected through telephone calls. Only 
patients with preoperative potency and bilateral nerve sparing surgery were 
subjected to IIEF scoring. Questionnaires were sent by post to patients who could 
not be reached by phone. The questionnaires were translated to the German 
language since it is the native language for the included patients. 
2.3.1. ICIQ 
 
ICIQ is a brief, fully validated questionnaire launched after the International 
Consultation on Incontinence meeting in 1999. This score is composed of the sum 
of three questions after the selection of one answer for each question. The first 
question is how often the patient leaks urine. The patient should select one of six 
answers (never, once a week, 2-3 times a week, once a day, several times a day or 
all the time) and score from 0 to 5. The second question is how much urine the 
patient leaks, and the answer is one of four (none = 0, small amount = 1, moderate 
amount = 2, large amount = 3). The third question is how much does leaking urine 
interfere with the patient’s everyday life, and the answer is a score between 0 and 
10. The ICIQ score is the sum of the previous three answers, and the degree of 
incontinence is classified into: no incontinence = 0, mild = 1-5, moderate = 6-10 and 
severe = 11-21. 
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2.3.2. IIEF score 
 
The International Index of Erectile Function (IIEF) is a validated questionnaire 
used for clinical assessment of erectile dysfunction and treatment outcomes (Rosen 
et al., 1997). The first five questions in the IIEF questionnaire assess the erectile 
function of patients. A score between 0-5 is awarded for each question. The first 
question is how often the patient can get an erection during sexual activity. The 
second is how often the erections were hard enough for penetration. The third is 
how often the patient was able to penetrate. The fourth is how often the patient was 
able to maintain his erection after penetration. The last question is how often the 
patient could maintain his erection to the completion of intercourse. 
2.4. Statistical Analysis 
 
For this study, statistical analysis was performed using the jmp V.12 software® 
(SAS Inc. Cary, USA). All data were presented as median and range for continuous 
variables, and as percentages for categorical variables. Mann- Whitney-U and 
Pearson x2 tests were employed to compare the continuous and categorical 
variables, respectively. Kaplan Meier curves were used to present the survival data 
with the Log-rank test for comparison. A p-value of <0.05 is regarded as significant. 
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3. Research Questions and Hypothesis 
 
The study aims to answer the following questions: is there any difference 
between conventional or subtrigonal techniques for RARP regarding operative time, 
intraoperative and postoperative complication rates? Can the preservation of the 
dorsal venous plexus decrease the intraoperative blood loss? What is the impact of 
the anatomical preservation of the retropubic and perivesical areas on functional 
outcomes? Is STRP oncologically safe as TPRP or not? 
The hypothesis of this study is that STRP is associated with less blood loss 
and carries better functional outcomes regarding postoperative continence and 
erectile function. It is also oncologically safe with similar oncological outcomes in 
comparison to TPRP. The rationale for this hypothesis was based on the fact that 
the subtrigonal approach is more anatomically preservative than the conventional 
one since the prostatic gland is completely excised from the Douglas pouch with the 
preservation of perivesical tissues; this is expected to improve functional outcomes. 
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4. Results 
4.1. Patient Criteria 
Group A included 126 patients who underwent operation between January 
2012 and June 2013 using TPRP. The median age of this group is 64 years (45- 
76), the median BMI is 27.2 kg/m2 (20.9-40) and the median preoperative PSA is 
7.4 ng/ml (0.4-28). Regarding the clinical staging of PCa, 44 (34.9%), 19 (15.0%) 
and 1 (0.07%) patients are T1, T2 and T3, respectively. The other 62 patients 
(49.2%) have clinical stages between T1-T3, however, the specific stage was 
unknown. D’ Amico risk stratification was applicable for only 61/126 patients as the 
following: Low 14 (23%), Moderate 36 (59%) and High 11 (18%). In this group, 26 
(21%), 47 (37%) and 53 (42%) had bilateral, unilateral or non-nerve sparing surgery, 
respectively. 
 
Group B included 62 patients who underwent operation between January 2014 
and January 2015 using STRP with a median age of 62.5 years (48-77), BMI median 
of 26.7 kg/m2 (21.2-37.8) and preoperative PSA median of 7.0 ng/ml (1.2- 
26.8). In this group, T1, T2 and T3 clinical stages are 22 (35.5%), 11(17.7%) and 0 
(0%), respectively. The other 29 (46.8%) patients were unknown. Risk stratification 
was Low, Moderate and High for 6 (19%), 17 (53%) and 9 (28%) patients, 
respectively. 8 (13%), 32 (52%) and 22 (35%) patients had bilateral, unilateral or 
non-nerve sparing radical prostatectomy. Both groups were matched in all previous 
variables with no significant difference detected (see Table 1). 
 
Table1: Preoperative criteria of patients involved in the study, including the p-value of the difference 
between both groups 
 
Patients criteria Group A Group B P 
Age (y) 64 (45-76) 62.5 (48-77) 0.13 
BMI (kg/m2) 27.2 (20.9-40) 26.7 (21.2-37.8) 0.33 
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Pre-Op PSA (ng/ml) 7.4 (0.4-28) 7.0 (1.2-26.8) 0.80 
Clinical stage* 
cT1 
cT2 
cT3 
Unknown 
 
44 (34.9%) 
19 (15.0%) 
1 (0.07%) 
62 (49.2%) 
 
22 (35.5%) 
11 (17.7%) 
0 
29 (46.8%) 
 
 
 
0.43 
D’ Amico risk 
stratification* 
Low 
Moderate 
High 
 
 
14 (23%) 
36 (59%) 
11 (18%) 
 
 
6 (19%) 
17 (53%) 
9 (28%) 
 
0.53 
Nerve sparing 
No 
Unilateral 
Bilateral 
 
53 (42%) 
47 (37%) 
26 (21%) 
 
22 (35%) 
32 (52%) 
8 (13%) 
 
 
 
0.11 
*Data were not available for all patients, ** Significant p-value 
 
 
 
4.2. Perioperative Outcomes 
 
 
The console time was comparable in both groups. In group A, the median time 
was 167 minutes (90-267) versus 163 (72-273) for group B (p=0.65). No difference 
was detected in blood loss between both groups; the median of haemoglobin drop 
was 2.73 (0-9.2) for group A versus 2.70 (0.5-6.6) in group B (p=0.80). The median 
time of post-operative catheterisation was 5.7 days (4-20) in 
28 
 
 
 
 
group A versus 5.5 (4-9) in group B (p=0.96); and the median hospital stay after 
surgery until discharge was 7 days (3-24) in group A and 7 days (5-14) in group B. 
The pathological findings were comparable in both groups; in group A, 17 (14%), 
74 (59%), 28 (22%) and 7 (6%) patients had the Gleason score of ≤6, 3+4, 
4+3 and ≥8, respectively, versus 10 (16%), 30 (48%), 19 (31%), 3 (5%) in group B. 
97 (77.0%) and 25 (19.8%) patients in group A displayed pT2 and T3 versus 45 
(72.6%) and 14 (22.6%) in group B (p=0.96). Pathological staging was missed in the 
pathology report for the other patients (4 and 3 patients in group A and B, 
respectively). pNx, N0 and N1 lymph node statuses were 1 (1%), 120 (95%) and 5 
(4%) in group A and 1 (1.6%), 58 (93.6%) and 3 (4.8%) in group B (p=0.58). Only 
the prostatic volume displayed a significant difference which was 46.5 g (14-173) in 
group A versus 38.5 g (16-84) in group B (p-value = 0.018). 
 
 
Table 2: Perioperative and pathological outcomes of patients involved in the study, including 
the p-value of the difference between both groups 
Perioperative outcomes Group A Group B P 
Console time (min) 167 (90-267) 163 (72--273) 0.65 
Blood loss by Hb diff. 2.73 (0-9.2) 2.70 (0.5-6.6) 0.80 
Intra op. complications 1 1 0.42 
Days of cath. 5.7 (4-20) 5.5 (4-9) 0.96 
Hospital stay (day) 7 (3-24) 7 (5-14) 0.06 
final Gleason 
 
<=6 
 
 
3+4 
 
 
 
 
17 (14%) 
 
 
74 (59%) 
 
 
10 (16%) 
 
 
30 (48%) 
 
 
 
 
0.16 
29 
 
 
 
 
4+3 
 
 
>=8 
28 (22%) 19 (31%)  
 
7 (6%) 
 
3 (5%) 
Pathological Stage* 
pT2 
pT3 
Unknown 
 
97 (77.0%) 
 
45 (72.6%) 
 
 
 
0.96 25 (19.8%) 14 (22.6%) 
4 (3.2%) 3 (4.8%) 
LN    
 
 
0.58 
pNx 1 (1%) 1 (1.6%) 
pN0 120 (95%) 58 (93.6%) 
pN1 5 (4%) 3 (4.8%) 
Prostatic weight (g) 46.5 (14-173) 38.5 (16-84) 0.018** 
*Data were not available for all patients, ** Significant p-value 
 
 
 
 
 
Table 3: Postoperative complications classified according to the Clavien-Dindo 
classification 
 
 
 
Clavien Group A No. (%) Group B No. (%) 
I -  -  
II Blood transfusion 1 (0.007%)   
IIIa   Retention + suprapubic 
catheter fixation 
1 (1.6%) 
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IIIb Lymphocele + 
Laparoscopic 
fenestration 
6 (4.8%) Lymphocele + 
Laparoscopic fenestration 
1 (1.6%) 
IVa Angina + ICU 
admission 
1 (0.007%)   
IVb -  -  
V -  -  
 
 
 
Regarding complications, one patient in each group developed intra- operative 
complications; obturator nerve injury in group A and left ureteral injury in group B. 
For postoperative complications, 8 patients (6.3%) developed postoperative 
complications in group A; one patient required blood transfusion, 6 patients 
developed pelvic lymphocele and treated with laparoscopic fenestration later on and 
one patient developed angina pectoris and was admitted to the intensive care unit 
for 2 weeks. On the other hand, only 2 patients developed post-operative 
complications in group B; one patient had acute urine retention due to urethral 
catheter blockage and was managed by supra pubic catheter fixation. The other 
patient developed pelvic lymphocele treated by laparoscopic fenestration. The 
difference in the complication rate between the two groups was not significant (p- 
value= 0.34). Postoperative complications according to the Clavien-Dindo 
classification are presented in Table 3. 
 
4.3. Functional Outcomes 
4.3.1. Continence 
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From the included 188 patients, 146 (77.7%) patients responded to our contact 
trials and answered the ICIQ questionnaire; 96 patients answered the phone calls 
and the other 50 patients completed the questionnaire form and sent it back by post. 
Group distribution was 93 patients in group A and 53 patients in group B. In group A, 
37/93 patients (40%) could achieve immediate postoperative continence versus 
23/53 patients (43%) in group B (p-value = 0.67). 
At 3, 6 and 12-month intervals, the continence recovery rates were 71%, 73% 
and 87% in  group A  versus 76%,  89%  and 96% in  group B.  P-values were0.55, 
0.02 and 0.054, respectively, with a significant difference at 6 months interval and 
near significant difference at 12 months. The median number of pads used per day 
was 0.4 in group A versus 0.6 in group B (p-value = 0.20). 
 
 
 
*significant p-value 
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Figure 9: Differences in continence rates between group A (blue) and group B (red) after 
catheter removal at 3, 6 and 12-month intervals after surgery. 
 
4.3.2. Erectile function 
A total number of 22 patients were eligible for postoperative assessment of 
erectile function; 15 patients in group A with the median age of 61 years (45-75), and 
7 patients in group B with the median age of 59 years (48-69). In group A, 2/15 (13%) 
patients could achieve enough erection for penetration versus 3/7 (43%) in group B; 
however, the difference was not significant (p-value = 0.13). The median IEFF score 
was 7.4 (1-25) in group A versus 11.6 (1-25) in group B (p-value = 0.72). 
 
 
 
Figure 10: The percentage of patients in each group that were able to penetrate after 
bilateral nerve sparing surgery. 
 
4.4. Oncological Outcomes 
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Positive surgical margin rates and BCR were used to compare the oncological 
outcomes in both groups. Overall, the positive surgical margin (PSM) rate was 16% 
in group A versus 8% in group B, (p-value = 0.11). When the PSM was compared in 
each pathological stage, the rates in pT2, pT3a and pT3b were 7.2%, 53% and 55.6% 
in group A versus 2.2%, 11% and 60% in group B, respectively (p-values = 0.19, 0.03 
and 0.87). The PSM in pT3a was significantly lower in group B than in group A. With 
the comparison of the PSM rate at the prostatic apex, group A was 9.8% versus 
group B which was 1.6%, with a significant difference (p-value = 0.02). 
 
 
*significant p-value 
Figure 11: The difference in PSM rates between both groups; the columns demonstrate the 
total PSM rates at the apex and in each pathological stage. 
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After a median follow-up time of 34 months (24-39) for group A and 9 months 
(3-15) for group B, the BCR 1y-free survival was 91% in group A compared to 94% 
in group B. Kaplan Meier curve in Figure 12 illustrates the BCR-free survival in both 
groups (Log-rank p-value = 0.57). 
 
 
 
 
Figure 12: Kaplan Meier diagram demonstrating the 1-year BCR-free survival; the red line 
represents group A and the blue line represents group B. 
 
 
 
 
5. Interpretation and Discussion 
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Although PCa is not aggressive in most cases, surgical treatment by RP in 
intermediate or high-risk diseases was approved to provide longer overall and 
disease-specific survivals for patients with localised PCa when compared to 
conservative treatment (Bill et al., 2014). Even in locally advanced PC with regional 
lymph node metastasis, RP was suggested to improve the survival outcomes (Engel 
et al., 2010; Fahmy et al., 2017). Despite being the preferred treatment option in 
localised PCa with a life expectancy of more than 10 years (Droz et al., 2010), there 
is no specific age limit for this operation and it shouldn’t be denied on the basis of 
age alone (Albertsen et al., 2011). Patients with high risk PCa or with a life 
expectancy of <10 years included in this study were operated after discussing other 
non-surgical therapeutic modalities. Despite higher financial cost, RARP replaced 
open RP as a gold standard treatment for localised PCa in USA and this trend is 
extending to Europe and other parts of the world (Naomi, 2014). 
The functional outcome, in the form of potency and continence, is the main 
concern for patients requiring RP, as well as the main reason to avoid this operation. 
Nerve sparing during RP can improve the functional outcome and can be safely 
performed in all patients with low-risk disease (Walsh, 2001). Even in patients with 
preoperative impotence, nerve sparing may help in continence preservation (Nilson 
et al., 2003). It is not recommended for patients with high-risk diseases, or those 
suspected of extracapsular extension due to higher risk of residual tumour (Steuber 
et al., 2006). Nerve sparing can be initially planned with the use of nomograms or 
Partin tables that can predict the involvement of NVB or based on preoperative 
multiparametric MRI scan (Partin et al., 1997; Iversen et al., 2010). However, the 
decision can be changed according to the intra-operative findings. Some techniques 
are very useful in making intra-operative decisions; frozen section analysis is very 
helpful for making a proper decision regarding nerve sparing (Beyer et al., 2014). 
Any induration detected by intra-operative palpation of the NVB area, which is an 
advantage for open surgery over 
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laparoscopic surgery, is highly suspicious of NVB invasion and should then be 
excised. 
RP can be performed open, laparoscopic or robotic assisted. The clear 
advantages of laparoscopic or robotic assisted versus open are reduced blood loss, 
faster recovery, earlier discharge and less operative pain, yet early oncological and 
functional outcomes are comparable to open surgery (Yaxley et al., 2016). The 
magnification and 3-dimensional vision provided in RARP make the challenging 
steps of nerve sparing and urethra-vesical anastomosis more feasible, and this is 
the main factor for the increasing popularity of RARP. Most commonly, RARP is 
performed through the transperitoneal approach, which is preferred by many 
surgeons due to the larger working space compared to the extraperitoneal 
approach. In this study, both used techniques are transperitoneal, however, the 
subtrigonal one is more anatomical preserving as the prostate is completely 
removed through the cul-de-sac. 
Only preliminary data is available in the literature about the outcome of STRP. 
In 2013, Bocciardi and group reported their results using STRP on 200 patients 
(Galfano et al., 2013). Another group presented their results at the Italian urology 
meeting in 2015 on 45 patients (Al-Shali et al., 2015). In contrast to our study, both 
reports did not compare subtrigonal to conventional RARP. Recently, a 
randomized controlled trial including 120 patients suggested that STRP can result 
in earlier recovery of continence in comparison to TPRP (Dalela et al., 2017). 
5.1. Perioperative Outcomes 
 
In general, the reported rates for perioperative complications after RARP are 
very low. For example, bladder neck contracture, anastomotic leak and post- 
operative ileus are about 1%. Other organ injury and deep venous thrombosis are 
less than 1% (Ramsay et al., 2012). We employed the Clavien-Dindo classification, 
the most commonly used classification in urological procedures, to report our 
postoperative complications (Clavien et al., 1992). 
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In this study, patients who underwent operation in the first 6 months after the 
switch to STRP were excluded from the start since it was during the learning phase 
of the new technique. The switch to STRP did not affect the perioperative outcomes 
regarding the operative time, blood loss, intra or postoperative complications. In 
STRP, the creation of vesico-urethral anastomosis is a challenging step due to the 
narrow working space in comparison to TPRP in which the bladder is mobilised; 
however, no anastomotic complications were recorded in our patients. 
Theoretically, operative time for RARP is the time starting from port fixation 
until the closure of port sites after the performance of surgery. Usually, port insertion 
and removal are conducted by assistant surgeons. In this study, port insertion and 
removal were the same in both cohorts. That is why we only compared the console 
time in both groups to investigate the impact of changing the operative technique on 
time. The estimation of blood loss during surgery can be done through different 
methods; by direct measurement from the surgical suction, or by weighing the 
gauzes and towels. It can also be estimated in the laboratory by comparing the pre 
and postoperative haemoglobin levels. Visual estimation (photometry) can also be 
used (Schorn, 2010). In Tuebingen’s database, blood loss in the surgical suction 
and pre and postoperative haemoglobin levels were recorded. We compared blood 
loss between TPRP and STRP by by the difference between pre and postoperative 
haemoglobin levels as we consider this method more clinically relevant than suction 
measures. 
 
5.2. Functional Outcomes 
 
5.2.1. Continence 
 
Functional outcomes in terms of urinary continence and potency is the main 
concern of patients regarding RP. After surgery, the prevalence of incontinence at 
1 month is high, ranging from 4% to 87%. However, incontinence tends to diminish 
with time, and recovery is observed in most cases during 1 to 6 months following 
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surgery (Cespedes et al., 1999; Jonler et al., 1996). By 12 months after surgery, 
90% of patients are continent, and this percentage can increase after one more year 
(Walsh et al., 1998; Catalona et al., 1999). About 6% of patients require surgical 
treatment for incontinence after RP (Kim et al., 2013). The severity of incontinence 
and the timeline of urinary function recovery depends on many preoperative and 
intraoperative factors. Preoperative factors include age, preoperative voiding 
function, reduced bladder compliance, detrusor hypertrophy, bladder outlet 
obstruction and neurological disorders. Body mass Index (BMI), especially if more 
than 30 Kg/m2, is associated with a higher rate of incontinence (Anast et al., 2005). 
Anatomical variations between patients can affect the outcome as well; some 
patients have underdeveloped striated sphincter with less muscle fibres and more 
collagen (Burnett & Mostwin, 1998; Strasser et al., 1999). The length of 
membranous urethra might have a direct impact on the continence rate after the 
removal of the prostate (Cambio & Evan, 2006). Normally, urine continence is 
maintained by the bladder neck and the external sphincter near the prostatic apex. 
Removal of the prostate through surgery disrupts the way the bladder holds urine 
and can result in urine leakage. This may be due to improper dissection of the 
prostatic base from the bladder neck. Post RP incontinence is usually secondary to 
intrinsic sphincter deficiency, which can be injured during the dorsal venous complex 
ligation and division. Preservation of a supple bladder neck without too large 
diameter is crucial for postoperative incontinence (Horrie et al., 1999). Using large 
and deep sutures for vesicourethral anastomosis can damage the continence 
provided by the urethral smooth muscles. Striated sphincter injury during the 
dissection of the prostatic apex should be avoided by careful apical dissection. 
Furthermore, pubovesical/puboprostatic ligaments are considered to play a role in 
the continence mechanism by stabilising the prostate, bladder and urethra in their 
positions (Steiner et al., 1994; Presti et al., 1990; Deliveliotis et al., 2002; Burnett et 
al., 1998). Preservation of NVB was suggested to not only preserve potency, but 
also improve continence outcome (Walz et al., 2016). 
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The subtrigonal approach for RP was first described by Bocciardi in 2010 as 
the most anatomically preserving approach for this operation (Galfano et al., 2010); 
by this technique, the prostate can be completely excised through the Douglas 
pouch with the preservation of all peri-vesical tissues, the Retzius space and the 
dorsal venous complex. All these structures were suggested to be involved in the 
continence mechanism, as mentioned above. Based on the evidence of variability 
in NVB distribution (Eichelberg et al., 2007; Sievert et al., 2008; Ganzer et al., 2008; 
Lee et al., 2008), NS through the subtrigonal approach is expected to preserve the 
entire circumferentially located fibres around the prostate, which is supposed to 
improve the functional outcome. 
The severity of the incontinence can be estimated by the number of pads used 
per day. In this study, incontinence was defined as using at least one pad per day. 
The assessment of post RP incontinence is a comprehensive process and should 
ideally be continuous at different time intervals, not only to assess the presence of 
incontinence, but also to accurately detect the change of symptoms with time. Even 
for research purposes, continence function should be preoperatively assessed to 
predict the outcome which depends on many factors, as previously mentioned. 
Despite not being routinely required, urodynamic study is a useful tool to detect the 
cause of post prostatectomy incontinence, and to assess the compliance of the 
bladder (Singla & Singla, 2014). Some conservative measures can help patients to 
faster recovery of incontinence after RP which can even be started before the 
operation; for example, weight reduction and pelvic floor exercises (Kegel exercises) 
(Kampen et al., 2000). Other measures include lifestyle modifications in the form of 
reduced fluid intake, avoidance of bladder irritants such as caffeine and alcohol as 
well as biofeedback (Goode et al., 2011). Furthermore, pharmacological agents 
such as anti-muscarinic agents can improve symptoms (Singla & Singla, 2014). 
In this study, the immediate postoperative continence after catheter removal 
was nearly similar in both the subtrigonal group and the conventional group. 
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Recoverability of continence was faster in the subtrigonal group. After 12 months, 
the continence rate was also higher in this group. Bocciadri and Al-Shali reported 
higher immediate postoperative continence (90% and 63%, respectively) than our 
results, however, this can be explained by the difference in patient criteria. Most of 
our patients (77.0%) were intermediate or high-risk PCa versus the 45% in 
Bocciardi’s report that theoretically may require more dissection and affect the 
urethral length (Hoyland et al., 2014). Our continence rate after one year was nearly 
similar to Bocciardi’s results. Due to the absence of detailed preoperative 
assessment of our patients’ continence status, all were supposed to be fully 
continent before surgery. 
Despite being promising, the results of our study should be cautiously 
interpreted because some important data about other factors were irretrievable. It 
was not documented whether any of the patients began pelvic floor exercises before 
or after RP, and if anyone followed a certain lifestyle plan to improve their symptoms. 
Furthermore, the data were collected from patients only once at a certain time, and 
patients depended on their memory to answer the given questionnaire. Therefore, 
the accuracy of the data given by patients might be affected. 
 
5.2.2. Erectile dysfunction 
 
Erectile dysfunction is one of the common side effects for RP and it can 
affect more than 60% of patients treated with this operation (Chung & Brock, 2013). 
The definition of erectile dysfunction varies among studies. It was defined as the 
ability to develop spontaneous erection (Ficarra et al., 2009), or the ability to have 
satisfying intercourse (Willis et  al., 2012). Preservation of erectile function after 
RP requires sparing of the neurovascular bundle. The feasibility of nerve sparing 
depends on numerous factors; firstly, the risk stratification of PCa. It is not advised 
to preserve the NVB in high-risk or palpable intraoperative tumour at the apex of 
the prostate due to the higher rate of positive margins in these cases (Steuber et 
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al., 2006). In addition, the anatomical variation in the distribution of NVB makes 
nerve sparing difficult if the nerve fibres are distributed all around the prostate or 
partially impeded inside the prostatic tissue (Ganzer et al., 2008; Lee et al., 2008). 
Regardless, the used surgical approach, cauterization, must be avoided to prevent 
thermal injury during NVB dissection; alternatively, it can be controlled by hemoclips 
(Salomon et al., 2004). Avoidance of traction and direct manipulation of NVB can 
minimise cavernous nerve injury. In addition, one of the main advantages of RARP 
is the magnification of the field and better visualisation of the prostatic apex and 
NVB. 
In the literature, there are some debates that postoperative fibrotic changes 
which occur in the corpus cavernosum are one of the causative factors of erectile 
dysfunction (Joseph et al., 2006). Indeed, cavernous nerve injury in animal models 
is associated with penile fibrosis and structural changes in the penis (Podlasek et 
al., 2001). In animal models, cavernous nerve injury resulted in severe neuropraxia 
with subsequent apoptosis of penile smooth muscle fibres and endothelium. This 
can cause increased production of transforming growth factor- beta and other 
fibroproliferative cytokines. Eventually, it can lead to the loss of smooth muscles and 
fibrosis. Rehabilitation after RP is more involved in postoperative management for 
faster recovery of erectile function and the prevention of penile shrinkage (Jae K and 
Seung L, 2015). Variable options can be used, for instance, phosphodiesterase- 
5 inhibitors, vacuum bumps and intracavernosal or intraurethral prostaglandin 
injections (Sheng Q et al., 2016). 
Although potency recoverability was higher in the subtrigonal group (43% 
versus 13% in the conventional group), the difference was not statistically significant 
since only patients who underwent bilateral NS with no history of ED (11.7%) were 
included in this comparison. Preoperative assessment of erectile function was only 
based on medical history. No IIEF score-based assessment was performed before 
surgery, which should be considered in future studies to assess potency outcomes 
after RP. This may add some limitation to our potency results. Furthermore, there 
are no available data of our patients practicing any kind of 
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penile rehabilitation using medications or vacuum devices. The data was collected 
at a certain point in time, not at different time intervals as for continence data. 
Moreover, our results regarding postoperative sexual function was lower than the 
reported results by Al-Shali et al. (51%) and Bocciardi et al. (75%). 
 
5.3. Oncological Outcomes 
 
5.3.1. Marginal status 
 
The best local control of PCa can be achieved by the complete removal of the 
prostate and the surrounding adventitia without breaching the tumour to avoid any 
residual malignant cells. Because most prostate adenocarcinomas arise from the 
peripheral zone, there is some chance for positive surgical margins. In fact, marginal 
status can be affected by several factors. For instance, localised tumours (pT2 or 
less) have much lower positive margin rates compared to locally advanced stages 
(T3 or higher). In high-volume centres, the reported positive margin rates for pT2 
ranged between 4% and 10%, and between 21% to 35% for pT3 (Patel et al., 2008; 
Stolzenburg et al., 2008). Surgical technique and experience can also affect the 
marginal status. As previously mentioned, apical dissection is a very challenging 
step to obtain a proper urethral length and to preserve the striated sphincter. This is 
why the prostatic apex is the most common site for positive margins (Touijer et al., 
2005). Furthermore, several authors have proven that the technique used for 
histopathological examination of the prostate specimen affects marginal results. 
Some studies only used biopsies of remaining tissue after the removal of the surgical 
specimen to assess margin status, while others employed step-sectioned routine or 
whole-mount histology. Routine sectioning detected a higher rate of positive margins 
because the tissue slices are thinner than that of the whole-mount technique and up 
to 12% of positive margins can be missed when the whole-mount technique is used 
(Cohen MB et al., 1994). 
In this study, all specimens were examined by the whole-mount technique for 
both groups, and surgical experience would unlikely affect the PSM results since 
43 
 
 
 
 
RARP has been well-established for many years in Tuebingen University hospital. 
The difference in PSM between the two groups is clearly due to the difference in 
surgical technique. Theoretically, the subtrigonal approach is expected to have only 
functional benefits since it is considered the least anatomically disturbing approach 
for RARP. Our oncological outcomes displayed obvious reduction in PSM rates, 
especially at the apex and in patients with extra-capsular tumours (pT3a). Our 
patients’ overall PSM after the subtrigonal approach was 8% versus 25.5%, as 
reported by Bocciardi (Galfano et al., 2013). The marked reduction of PSM at the 
apex and pT3a in STRP in comparison to TPRP can be explained by the difference 
in the peri-prostatic dissection; in STRP we used the “single plane continuous 
dissection”. After the dissection of the bilateral seminal vesicles, the dissection 
around the entire prostate is performed from the same plane guided by the prostatic 
capsule. Therefore, only one plane for dissection is first created on the seminal 
vesicles away from the prostate itself. The counter traction applied by the assistant 
surgeon on the seminal vesicles makes it easier to identify the prostatic capsule and 
the suspected macroscopic extracapsular extension of the tumour. On the other 
hand, the dissection in TPRP is the “multiple planes interrupted dissection”. After 
the dissection of the bilateral seminal vesicles and the posterolateral aspects of the 
prostate, we created another plane anteriorly through the retro-pubic space. No 
specific landmarks can identify the proper plane away from the prostate as in the 
case of the seminal vesicles, which may increase the probability of exceeding the 
capsule during the identification of the proper plane. This can further explain the 
high PSM rate in pT3b (seminal vesicle invasion) in both groups where the plane is 
created, with the high probability of dissecting through the tumour during the 
identification of the dissection plane. 
 
5.3.2. Biochemical recurrence 
 
After RP, the PSA level should be undetectable provided that the entire 
prostatic tissue was removed. In general, about 25% to 41% of patients can 
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develop increased PSA within 10 years after RP, however, this doesn’t mean that 
these patients will develop clinical progression or metastasis (Roehl et al., 2004). A 
slight rise of PSA can be due to residual benign or malignant prostatic tissue or may 
be due to non-prostatic origin of PSA (Diamandis & Yu, 1995). Nonetheless, a raised 
PSA should be considered as an indicator for residual or recurrent tumour unless it 
is very low and shows plateau levels on serial follow-ups. Surgical margin status, 
with consideration of pathological stage, is an important predictor for BCR. Patients 
with pT2 disease and positive margins have a 12% higher risk of BCR than those 
with same stage and negative margins. This risk can increase to 18% in the pT3b 
stage (Budaus et al., 2010). The median time to develop metastasis after BCR is 
about 8 years, but this also depends on the PSA doubling time and the postoperative 
Gleason score (Antonarakis et al., 2012). The impact of time between RP and BCR 
on metastasis and mortality is controversial in the available reports; the prostate 
cancer–specific mortality risk decreases by 24% for every year delayed from surgery 
to BCR, (Freedland et al., 2006). On the other hand, in a cohort of patients with BCR 
who did not receive either adjuvant therapies, the time from prostatectomy to 
biochemical recurrence was not significantly associated with systemic progression 
(Boorjian et al., 2011). 
An accurate definition of BCR was a matter of debate for many years. In fact, 
more than 50 definitions were reported in the literature (Zincke et al., 1994; Moul et 
al., 1996; Cookson et al., 2007). Different values for PSA were used as a cut-off for 
the definition of BCR. Eventually, the American Urological Association (AUA) 
guidelines panel defined BCR as a PSA of 0.2 ng/mL or greater with a second 
confirmatory reading (Cookson et al., 2007). Currently, this the most commonly used 
definition in clinical practice, and it was applied in our study as well. 
In this study, we only compared the 1-year BCR-free survival as the maximal 
follow-up for the subtrigonal group, which was 15 months. Our results in the 
subtrigonal group was 94% BCR-free survival in comparison to the 90% reported by 
Bocciardi. This is considered a short period; a longer follow-up must be considered 
in future studies. 
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In conclusion, the more anatomical preservation by using STRP was 
suggested to increase the postoperative continence recoverability. This study 
approved the oncological safety of STRP, even in locally advanced cases. 
Surprisingly, the subtrigonal approach displayed a reduction of PSM; especially at 
the apex and in tumours with extra-capsular extension. The results of this study 
should be interpreted with consideration of the highlighted limitations in the 
discussion, as well as the short duration of the follow-up. Prospective studies that 
include a larger number of patients and with longer follow-ups are mandatory to 
confirm or deny these results. 
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6. Abstract/Summary 
 
6.1. Background 
 
The subtrigonal approach for robotic assisted radical prostatectomy was first 
described in 2010 as the most anatomically preserving technique, in which the 
prostate can be completely removed through the Douglas pouch. This technique 
was introduced in the Urology Department of Tuebingen University Hospital in June 
2013 after many years of performing the conventional transperitoneal robotic 
prostatectomy, however few data is available regarding its outcome. 
6.2. Objectives 
 
The aim of this study is to compare the functional and oncological outcomes 
of subtrigonal approach versus the conventional approach for robotic radical 
prostatctomy 
6.3. Methods 
 
Consecutive groups of patients who underwent TPRP (n=126) from 01/2012 
to 05/2013, and those who switched and underwent STRP (n=62) from 01/2014 to 
01/2015 were compared;. Functional outcomes were evaluated using ICIQ and IIEF 
of both groups by questionnaire and telephone protocols. Oncological outcomes 
were assessed regarding positive surgical margins and biochemical recurrence free 
survival (PSA ≥ 0.02 ng/ml) using the Kaplan Meier curve. Postoperative 
complications were classified using the Clavien-Dindo system. Statistical analysis 
was performed using the jmp v.12 software®. Mann-Whitney-U and Pearson x2 tests 
were employed to compare the continuous and categorical variables, respectively. 
The Kaplan Meier curve was applied to present the survival data 
6.4. Results 
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The median age and follow-up time in the TPRP and STRP groups were 64 
and 62.5 years and 34 and nine months, respectively. Within 7 days of catheter 
removal, 37/93 patients (40%) in group A were continent compared to 23/53 (43%) 
in group B (p-value = 0.67). At 3, 6 and 12-month intervals, the continence recovery 
rates were 71%, 73% and 87% in group A versus 76%, 89% and 96% in 
group B. The p-values were 0.55, 0.02 and 0.054, respectively. 15 and 7 patients in 
group A and B, respectively, underwent bilateral nerve sparing surgery (NS). In 
group A, 2/15 (13%) could achieve enough erection for penetration versus 3/7 (43%) 
in group B; (p-value = 0.13). The overall positive surgical margin (PSM) rate was 
16% in group A versus 8% in group B (p-value = 0.11). According to the pathological 
stage, PSM rates in pT2, pT3a and pT3b were 7.2%, 53% and 55.6% in group A 
compared to 2.2%, 11% and 60% in group B, respectively (p-values = 0.19, 0.03 
and 0.87). PSM in pT3a was significantly lower in group B. When comparing the 
PSM rate at the prostatic apex, it was 9.8% in group A versus 1.6% in group B; with 
a significant difference (p-value = 0.02). The BCR 1y-free survival was 91% in group 
A versus 94% in group B (Log-rank p-value = 0.57). 
6.5. Conclusion 
 
The anatomical preservative sub-trigonal approach for RARP increases the 
post-operative continence recoverability. Our results approved the oncological 
safety of this technique even in locally advanced cases. Sub-trigonal approach 
displayed reduction of PSM especially at the apex and in tumors with extra- 
capsular extension. Prospective randomized studies including bigger cohorts of 
patients with longer follow up are mandatory to confirm these results. 
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7. Abstrakt / Zusammenfassung 
 
7.1. Hintergrund 
 
Der subtrigonale Ansatz zur robotergestützten radikalen Prostatektomie wurde 
erstmals in 2010 als die am besten die Anatomie erhaltende Technik beschrieben. 
Hierbei wird die Prostata vollständig durch den Douglas-Raum entfernt.. Diese 
Technik wurde im Juni 2013 in der Urologischen Klinik des Universitätsklinikums 
Tübingen eingeführt, nachdem viele Jahre lang die konventionelle transperitoneale 
robotische Prostatektomie durchgeführt worden war. Es liegen jedoch nur wenige 
Daten zum Ergebnis der neuen Technik vor. 
7.2. Ziele 
 
Das Ziel dieser Studie ist es, die funktionellen und onkologischen Ergebnisse des 
subtrigonalen Ansatzes mit dem konventionellen Ansatz für die robotische radikale 
Prostatektomie zu vergleichen. 
7.3. Methoden 
 
Konsekutive Gruppen von Patienten, die einer TPRP (n = 126), von 01/2012 bis 
05/2013, unterzogen wurden und diejenigen, die einer STRP (n = 62) von 01/2014 
bis 01/2015 unterzogen wurden, wurden verglichen. Funktionelle Ergebnisse 
wurden mittels ICIQ und IIEF beider Gruppen, erhoben durch Fragebogen und 
Telefonprotokollen, ausgewertet. Die onkologischen Ergebnisse wurden hinsichtlich 
der positiven chirurgischen Ränder und des biochemischen rezidivfreien 
Überlebens (PSA ≥ 0,02 ng/ml) mittels Kaplan-Meier-Kurve bewertet. Postoperative 
Komplikationen wurden nach dem Clavien-Dindo-System klassifiziert. Die 
statistische Analyse wurde mit der Software jmp v.12 durchgeführt. Mann-Whitney- 
U- und Pearson-x2-Tests wurden verwendet, um die kontinuierlichen bzw. 
kategorischen Variablen zu vergleichen. Die Kaplan-Meier- Kurve wurde 
angewendet, um die Überlebensdaten darzustellen. 
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7.4. Ergebnisse 
 
Das mittlere Alter und die Nachbeobachtungszeit in den Gruppen TPRP und STRP 
betrugen 64 bzw. 62,5 Jahre und 34 bzw. 9 Monate. Innerhalb von 7 Tagen nach 
Katheterentfernung waren 37/93 Patienten (40%) in Gruppe A kontinent verglichen 
mit 23/53 (43%) in Gruppe B (p-Wert = 0,67). In 3, 6 und 12-Monats- Intervallen 
waren die Kontinenzraten 71%, 73% und 87% in Gruppe A und 76% 
(p-Wert = 0,55), 89% (p-Wert = 0,02) und 96% (p-Wert = 0,054) in Gruppe B. Bei 15 
bzw. 7 Patienten der Gruppen A und B wurde eine bilaterale nervenschonende 
Operation (NS) durchgeführt. In der Gruppe A konnten 2/15 (13%) eine 
ausreichende Erektion für die Penetration erzielen, gegenüber 3/7 (43%) in der 
Gruppe B; (p-Wert = 0,13). Die Rate der positiven Absetzungsränder (PSM - positiv 
surgical margin) betrug in der Gruppe A 16% hingegen 8% in der Gruppe B (p-Wert 
= 0,11). Nach dem pathologischen Stadium betrugen die PSM-Raten 7,2%, beipT2, 
53% bei pT3a und 55,6% bei pT3b Gruppe A und im Vergleich 2,2% (p-Wert = 0,19), 
11% (p-Wert = 0,03) und 60% (p-Wert = 0,87) in Gruppe B. PSM in pT3a war in 
Gruppe B signifikant niedriger. Beim Vergleich der PSM-Rate am Apex der Prostata 
betrug sie 9,8% in Gruppe A gegenüber 1,6% in Gruppe B; mit signifikantem 
Unterschied (p-Wert = 0.02). Das Ein-Jahres-BCR-freie Überleben betrug 91% in 
Gruppe A gegenüber 94% in Gruppe B (logarithmischer Rang p-Wert = 0,57). 
7.5. Schlussfolgerung 
 
Der subtrigonale anatomische Konservierungsansatz für RARP erhöht die 
postoperative Kontinenzwiederherstellbarkeit. Unsere Ergebnisse bestätigten die 
onkologische Sicherheit dieser Technik auch in lokal fortgeschrittenen Fällen. Der 
subtrigonale Ansatz zeigte eine Reduktion des PSM, insbesondere am Apex und 
bei Tumoren mit extrakapsulärer Extension. Prospektive randomisierte Studien 
einschließlich größerer Kohorten von Patienten mit längerer Nachbeobachtung sind 
obligatorisch, um diese Ergebnisse zu bestätigen. 
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